Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2019-03-11 Director's Dealing
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
PDMR Dealing
Director's Dealing Classification · 1% confidence The document explicitly details a purchase of ordinary shares by Dr. David Ebsworth, the Chairman of Verona Pharma plc. It includes specific transaction details (date, price, volume) and is structured as a notification required under the EU Market Abuse Regulation. This content directly corresponds to the definition of Director's Dealing (insider trades by executives/directors).
2019-03-11 English
PDMR Dealing
Director's Dealing Classification · 1% confidence The document explicitly details the purchase of ordinary shares by Dr. David Ebsworth, the Chairman of Verona Pharma plc. It includes specific transaction details (date, price, volume) and is structured as a notification following the EU Market Abuse Regulation, identifying the person discharging managerial responsibilities. This content directly corresponds to the definition of Director's Dealing (insider trades by executives/directors).
2019-03-07 English
PDMR Dealing
Director's Dealing Classification · 1% confidence The document explicitly details the purchase of ordinary shares by Dr. David Ebsworth, the Chairman of Verona Pharma plc. It includes specific transaction details (date, price, volume) and is structured as a notification under the EU Market Abuse Regulation, reporting on the personal share transactions of a person discharging managerial responsibilities (PDMR). This perfectly matches the definition of Director's Dealing (insider trades). Document length is short (2889 chars), but the content is the primary disclosure itself, not an announcement of a report, thus DIRS is the correct classification over RPA or RNS.
2019-03-05 English
SFX-01 data published in peer reviewed journal
Earnings Release Classification · 1% confidence The document begins with 'RNS Number : 8089R' and is dated 05 March 2019. It announces the publication of scientific data regarding the company's product SFX-01 in a peer-reviewed journal. The text concludes with standard boilerplate information referencing RNS, the news service of the London Stock Exchange, and states that RNS is approved to act as a Primary Information Provider. This structure strongly indicates a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or CAP). Since it is a general regulatory announcement that doesn't fit other specific categories, the fallback code RNS is appropriate. FY 2019
2019-03-05 English
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
Regulatory Filings Classification · 1% confidence The document is a press release dated March 04, 2019, issued by Verona Pharma plc. It announces positive interim efficacy and safety data from a Phase 2 clinical trial of ensifentrine DPI formulation in COPD patients. The text details study results (FEV1 measurements), plans for the next phase of the trial, and provides background information on the drug and the disease. This structure—announcing key results and future plans following clinical trial progress—is characteristic of an Earnings Release (ER) or a general corporate update, but since it is focused on clinical trial data rather than quarterly financial performance highlights, it fits best under the category of a significant corporate announcement that is not a formal financial report (like 10-K or IR). Given the options, this is a high-level announcement of clinical progress, which often accompanies or precedes a formal earnings report, but the content itself is focused on R&D milestones. Since it is not a transcript (CT), a formal financial report (10-K, IR), or a presentation (IP), and it is a direct announcement of results, it most closely aligns with an Earnings Release (ER) if we interpret ER broadly as a period result announcement, or potentially Regulatory Filing (RNS) as a fallback. However, in the context of biopharma, clinical trial updates are often treated as key performance indicators announced via press release, similar to earnings highlights. Since it is not a formal financial report, and it is a specific announcement of trial results, I will classify it as an Earnings Release (ER) as it reports on the 'performance' of the drug candidate, or RNS if ER is strictly financial. Given the options, and the nature of reporting clinical milestones, ER is often used for such key operational updates in pharma/biotech. However, looking closely at the definitions, ER is for 'periodical financial results (key highlights only)'. This is a clinical trial result. Therefore, the most appropriate category for a non-standard, significant corporate announcement that isn't explicitly defined elsewhere (like M&A, Capital Change, etc.) is the fallback, Regulatory Filings (RNS). It is a formal announcement disseminated to the public/market.
2019-03-04 English
Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content announces the 'Total Voting Rights' as of a specific date (February 28, 2019), detailing the total number of ordinary shares (101,462,537). This type of announcement, which provides a mandatory regulatory update regarding share capital structure and voting rights denominator, fits best under the general 'Regulatory Filings' category (RNS) as it is not specifically covered by other codes like DIV, SHA, or DVA (which is for voting *results*). Given the explicit RNS identification and the nature of the announcement, RNS is the most appropriate classification.
2019-02-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.